Open AccessThe Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RA) in Diabetes-Related Neurodegenerative Diseases
Author(s) -
Dihe Cheng,
Shuo Yang,
Xue Zhao,
Guixia Wang
Publication year - 2022
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
ISSN - 1177-8881
DOI - 10.2147/dddt.s348055
Subject(s) - medicine , diabetes mellitus , neuroprotection , disease , type 2 diabetes , liraglutide , bioinformatics , glucagon like peptide 1 , glucagon like peptide 1 receptor , pharmacology , receptor , endocrinology , agonist , biology
Recent clinical guidelines have emphasized the importance of screening for cognitive impairment in older adults with diabetes, however, there is still a lack of understanding about the drug therapy. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are widely used in the treatment of type 2 diabetes and potential applications may include the treatment of obesity as well as the adjunctive treatment of type 1 diabetes mellitus in combination with insulin. Growing evidence suggests that GLP-1 RA has the potential to treat neurodegenerative diseases, particularly in diabetes-related Alzheimer's disease (AD) and Parkinson's disease (PD). Here, we review the molecular mechanisms of the neuroprotective effects of GLP-1 RA in diabetes-related degenerative diseases, including AD and PD, and their potential effects.